818 related articles for article (PubMed ID: 9840138)
21. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma.
Sterling RK; Jeffers L; Gordon F; Venook AP; Reddy KR; Satomura S; Kanke F; Schwartz ME; Sherman M
Clin Gastroenterol Hepatol; 2009 Jan; 7(1):104-13. PubMed ID: 18849011
[TBL] [Abstract][Full Text] [Related]
22. Development of a novel assay to quantify serum human telomerase reverse transcriptase messenger RNA and its significance as a tumor marker for hepatocellular carcinoma.
Miura N; Maruyama S; Oyama K; Horie Y; Kohno M; Noma E; Sakaguchi S; Nagashima M; Kudo M; Kishimoto Y; Kawasaki H; Hasegawa J; Shiota G
Oncology; 2007; 72 Suppl 1():45-51. PubMed ID: 18087181
[TBL] [Abstract][Full Text] [Related]
23. Clinical characteristics among patients with hepatocellular carcinoma according to the serum levels of alpha-fetoprotein and des-y-carboxy prothrombin.
Dohmen K; Shigematsu H; Irie K; Ishibashi H
Hepatogastroenterology; 2003; 50(54):2072-8. PubMed ID: 14696467
[TBL] [Abstract][Full Text] [Related]
24. The des-gamma-carboxyprothrombin for the diagnosis of hepatocellular carcinoma.
Brunello F; Marcarino C; Pasquero P; Gastaldi P; Gonella S; Martini S; Calcamuggi G; Emanuelli G
Ital J Gastroenterol; 1993 Jan; 25(1):9-12. PubMed ID: 7679014
[TBL] [Abstract][Full Text] [Related]
25. [Optimal cut-off value of PIVKA-II for diagnosis of hepatocellular carcinoma--using ROC curve].
Kim MJ; Bae KW; Seo PJ; Jeong IK; Kim JH; Lee BH; Bang KT; Kim DW; Song IH
Korean J Hepatol; 2006 Sep; 12(3):404-11. PubMed ID: 16998292
[TBL] [Abstract][Full Text] [Related]
26. Clinical evaluation of plasma abnormal prothrombin (PIVKA-II) in patients with hepatocellular carcinoma.
Fujiyama S; Morishita T; Sagara K; Sato T; Motohara K; Matsuda I
Hepatogastroenterology; 1986 Oct; 33(5):201-5. PubMed ID: 2433199
[TBL] [Abstract][Full Text] [Related]
27. Distribution of the heterogeneity of des-gamma-carboxyprothrombin in patients with hepatocellular carcinoma.
Uehara S; Gotoh K; Handa H; Tomita H; Senshuu M
J Gastroenterol Hepatol; 2005 Oct; 20(10):1545-52. PubMed ID: 16174072
[TBL] [Abstract][Full Text] [Related]
28. A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma.
Ertle JM; Heider D; Wichert M; Keller B; Kueper R; Hilgard P; Gerken G; Schlaak JF
Digestion; 2013; 87(2):121-31. PubMed ID: 23406785
[TBL] [Abstract][Full Text] [Related]
29. [Clinical usefulness of plasma PIVKA-II assay and its limitations in patients with hepatocellular carcinoma].
Fujiyama S; Morishita T; Shibata J; Sato T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1129-38. PubMed ID: 2471453
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
[TBL] [Abstract][Full Text] [Related]
31. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group.
Ishii M; Gama H; Chida N; Ueno Y; Shinzawa H; Takagi T; Toyota T; Takahashi T; Kasukawa R
Am J Gastroenterol; 2000 Apr; 95(4):1036-40. PubMed ID: 10763956
[TBL] [Abstract][Full Text] [Related]
32. Prognostic and diagnostic value of des-γ-carboxy prothrombin in liver cancer.
Bertino G; Ardiri AM; Calvagno GS; Bertino N; Boemi PM
Drug News Perspect; 2010 Oct; 23(8):498-508. PubMed ID: 21031166
[TBL] [Abstract][Full Text] [Related]
33. Des-gamma-carboxy prothrombin (DCP) ratio is a useful prognostic tumor marker for single nodule hepatocellular carcinoma (HCC).
Murakami N; Tamano M; Yoneda M; Sugaya H; Hiraishi H
Hepatogastroenterology; 2008; 55(81):197-201. PubMed ID: 18507106
[TBL] [Abstract][Full Text] [Related]
34. Des-gamma-carboxy prothrombin in cancer and non-cancer liver tissue of patients with hepatocellular carcinoma.
Tang W; Miki K; Kokudo N; Sugawara Y; Imamura H; Minagawa M; Yuan LW; Ohnishi S; Makuuchi M
Int J Oncol; 2003 May; 22(5):969-75. PubMed ID: 12684661
[TBL] [Abstract][Full Text] [Related]
35. [Decarboxyprothrombin: importance in the diagnosis of hepatocellular carcinoma].
Bon C; Brillard B; Gelineau MC; Mailliavin A; Trépo C; Pichot J
Ann Biol Clin (Paris); 1998; 56(2):175-81. PubMed ID: 9754243
[TBL] [Abstract][Full Text] [Related]
36. Plasma abnormal prothrombin levels in patients with small hepatocellular carcinoma.
Tanabe Y; Ohnishi K; Nomura F; Iida S
Am J Gastroenterol; 1988 Dec; 83(12):1386-9. PubMed ID: 2461655
[TBL] [Abstract][Full Text] [Related]
37. Serum des-gamma-carboxyprothrombin concentration determined by the avidin-biotin complex method in small hepatocellular carcinomas.
Saitoh S; Ikeda K; Koida I; Tsubota A; Arase Y; Chayama K; Kumada H
Cancer; 1994 Dec; 74(11):2918-23. PubMed ID: 7525036
[TBL] [Abstract][Full Text] [Related]
38. Elevation of serum type IV collagen in liver cancer as well as liver cirrhosis.
Hong WS; Hong SI; Park SY; Son Y; Lee YS; Chung YH; Yang SK; Suh DJ; Min YI
Anticancer Res; 1995; 15(6B):2777-80. PubMed ID: 8669863
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of abnormal prothrombin (DCP) in relation to postoperative survival and prognosis in patients with hepatocellular carcinoma.
Inoue S; Nakao A; Harada A; Nonami T; Takagi H
Am J Gastroenterol; 1994 Dec; 89(12):2222-6. PubMed ID: 7526679
[TBL] [Abstract][Full Text] [Related]
40. Des-gamma-carboxyprothrombin expression in cancer and/or non-cancer liver tissues: association with survival of patients with resectable hepatocellular carcinoma.
Tang W; Kokudo N; Sugawara Y; Guo Q; Imamura H; Sano K; Karako H; Qu X; Nakata M; Makuuchi M
Oncol Rep; 2005 Jan; 13(1):25-30. PubMed ID: 15583797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
